Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0012739 (
disseminated intravascular coagulation
)
8,673
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
We previously prepared cell lines that inducibly overexpress
MAP4
, a microtubule (MT)-associated protein widely expressed in non-neuronal cells. Overexpression of either the full-length
MAP4
molecule or its MT-binding domain, MTB, stabilized MTs and retarded cell growth, suggesting that overexpressed
MAP4
impacts on MT-dependent functions in vivo. To test this hypothesis, we examined MT-based vesicle movements in living cells, using high resolution
DIC
microscopy. Overexpression of either
MAP4
or MTB yielded a dose-dependent reduction in the frequency of MT-dependent organelle movements, relative to control cells. At steady state, both
MAP4
- and MTB-overexpressing cells showed unusual distributions of transferrin, LDL, dextran, and Golgi elements, as compared to control cells.
MAP4
preferentially inhibited receptor-dependent uptake and degradation of LDL, and repositioning of Golgi elements after disruption by the drug, brefeldin A. L-MOCK cells treated with Taxol to stabilize the MTs to an extent equivalent to
MAP4
overexpression did not show similar inhibition of vesicle motility or organellar trafficking, suggesting that deficits in organelle movements in vivo represent a direct effect of the presence of
MAP4
or MTB, rather than an indirect effect of the stabilization of MTs by overexpressed MAP constructs. Our results show that
MAP4
has the capacity to affect transport along MTs in vivo; these findings suggest a potential mechanism by which
MAP4
could contribute to polarization or morphogenesis of cells.
...
PMID:Overexpression of MAP4 inhibits organelle motility and trafficking in vivo. 936 75